These are the top 10 stock plays for 2023, according to UBS

As the twelvemonth winds down, investors are looking guardant to 2023 and wondering wherever they should spot their apical bets.

Analysts that screen companies are mulling the aforesaid question, prompting UBS to enactment unneurotic a database of its apical condemnation picks for 2023.

The database includes the firms "most compelling Buy-rated concern ideas for the twelvemonth ahead," strategist Keith Parker wrote successful a Dec. 13 note.

"We've focused connected stocks wherever we judge our analysts person a differentiated presumption vs. consensus, and wherever we person absorbing oregon proprietary information sources (from UBS Evidence Lab oregon elsewhere)," helium said. "We person besides considered imaginable upside to terms people and risk/reward skew arsenic good arsenic a stock's vulnerability to cardinal themes and origin preferences from a strategy perspective."

UBS apical picks for 2023

The apical picks from UBS span industries from wellness attraction to industrials and see a scope of expected upside from analysts.

The banal which is poised for the largest summation is Kymera Therapeutics, a biotechnology steadfast that UBS thinks could surge 240% to its people price.

"We spot important worth from KYMR's level successful full macromolecule degradation and spot them arsenic a person successful a disruptive field," wrote expert Eliana Merle. "Beyond this, we spot upside imaginable from occurrence successful immoderate 1 of KYMR's 4 objective signifier programs."

She added that UBS expects updates crossed each 4 programs successful the adjacent word arsenic good arsenic implicit 2023.

Zebra Technologies is different institution wherever UBS sees a ample upside of 77% arsenic the trends of automation and digitization continue.

"Shares are oversold connected abbreviated rhythm vulnerability and the misperception arsenic a one-off Covid beneficiary, successful our view," wrote Damian Karas, adding that helium believes the company's solutions offering volition assistance supply-chain and labour challenges. "We expect a important borderline step-up successful the adjacent fewer quarters and amended than expected guidance for 2023 to catalyze shares."

Other exertion companies connected the database see Advanced Micro Devices, Gitlab and Dell Technologies.

The 1 vigor sanction that UBS sees arsenic a apical prime for adjacent twelvemonth is Cheniere. The steadfast views Cheniere arsenic having coagulated 55% upside owed to its vulnerability to the liquid earthy state industry, which has been under-supplied.

"Cheniere has raised its '22 EBITDA guidance aggregate times this twelvemonth and continues to optimize its capableness allowing for further cargoes to beryllium unfastened to the spot marketplace astatine charismatic margins," said Brian Reynolds. "Given existent leverage metrics and guardant '23e FCFaD output of 14.7% – we proceed to presumption Cheniere positively arsenic it transitions from a de-leveraging communicative to a instrumentality of superior communicative with a steadfast maturation backlog (that is self-funded)."

The database besides includes concern names Array Technologies and Dycom Industries. Real property sanction Zillow Group and Endeavor Group Holdings circular retired the stocks with the largest upside.